1 |
Richter, K., Haslbeck, M. and Buchner, J. 2010. The heat shock response: life on the verge of death. Mol. Cell 40, 253-266.
DOI
|
2 |
Roussakow, S. 2013. The History of Hyperthermia Rise and Decline. Conference Papers in Medicine 2013, http://dx.doi.org/10.1155/2013/428027.
|
3 |
Sanchez-Ortiz, R. F., Tannir, N., Ahrar, K. and Wood, C. G. 2003. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J. Urol. 170, 178-179.
DOI
|
4 |
Sapareto, S. A. and Dewey, W. C. 1984. Thermal dose determination in cancer therapy. Int. J. Radiat. Oncol. Biol. Phys. 10, 787-800.
DOI
|
5 |
Shamovsky, I. and Nudler, E. 2008. New insights into the mechanism of heat shock response activation. Cell Mol. Life Sci. 65, 855-861.
DOI
|
6 |
Savina, A., Furlan, M., Vidal, M. and Colombo, M. I. 2003. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 278, 20083-20090.
DOI
|
7 |
Schlom, J. 2012. Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer Inst. 104, 599-613.
DOI
|
8 |
Schmitt, E., Maingret, L., Puig, P. E., Rerole, A. L., Ghiringhelli, F., Hammann, A., Solary, E., Kroemer, G. and Garrido, C. 2006. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 66, 4191-4197.
DOI
|
9 |
Shen, R. N., Lu, L., Young, P., Shidnia, H., Hornback, N. B. and Broxmeyer, H. E. 1994. Influence of elevated temperature on natural killer cell activity, lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells. Int. J. Radiat. Oncol. Biol. Phys. 29, 821-826.
DOI
|
10 |
Shevtsov, M. and Multhoff, G. 2016. Heat shock proteinpeptide and HSP-based immunotherapies for the treatment of cancer. Front. Immunol. 7, 171.
|
11 |
Siemann, D. W. and Horsman, M. R. 2015. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol. Ther. 153, 107-124.
DOI
|
12 |
Srivastava, P. K. and Amato, R. J. 2001. Heat shock proteins: the ′Swiss Army Knife′ vaccines against cancers and infectious agents. Vaccine 19, 2590-2597.
DOI
|
13 |
Srivastava, P. K. and Udono, H. 1994. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6, 728-732.
DOI
|
14 |
Starnes, C. O. 1992. Coley's toxins in perspective. Nature 357, 11-12.
DOI
|
15 |
Valenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corbelli, A., Fais, S., Parmiani, G. and Rivoltini, L. 2006. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 66, 9290-9298.
DOI
|
16 |
Tonkiss, J. and Calderwood, S. K. 2005. Regulation of heat shock gene transcription in neuronal cells. Int J Hyperthermia 21, 433-444.
DOI
|
17 |
Toraya-Brown, S. and Fiering, S. 2014. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int. J. Hyperthermia 30, 531-539.
DOI
|
18 |
Udono, H. and Srivastava, P. K. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152, 5398-5403.
|
19 |
van der Zee, J. 2002. Heating the patient: a promising approach? Ann. Oncol. 13, 1173-1184.
DOI
|
20 |
Voellmy, R. 1994. Transduction of the stress signal and mechanisms of transcriptional regulation of heat shock/stress protein gene expression in higher eukaryotes. Crit. Rev. Eukaryot. Gene Expr. 4, 357-401.
|
21 |
Whitesell, L. and Lin, N. U. 2012. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim. Biophys. Acta 1823, 756-766.
DOI
|
22 |
Whitesell, L. and Lindquist, S. 2009. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin. Ther. Targets 13, 469-478.
DOI
|
23 |
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S. and Zitvogel, L. 2001. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7, 297-303.
DOI
|
24 |
Zhang, Y., Huang, L., Zhang, J., Moskophidis, D. and Mivechi, N. F. 2002. Targeted disruption of hsf1 leads to lack of thermotolerance and defines tissue-specific regulation for stress-inducible Hsp molecular chaperones. J. Cell Biochem. 86, 376-393.
DOI
|
25 |
Wust, P., Hildebrandt, B., Sreenivasa, G., Rau, B., Gellermann, J., Riess, H., Felix, R. and Schlag, P. M. 2002. Hyperthermia in combined treatment of cancer. Lancet Oncol. 3, 487-497.
DOI
|
26 |
Yang, H. X. and Mitchel, R. E. 1991. Hyperthermic inactivation, recovery and induced thermotolerance of human natural killer cell lytic function. Int. J. Hyperthermia 7, 35-49.
DOI
|
27 |
Yao, Y., Wang, C., Wei, W., Shen, C., Deng, X., Chen, L., Ma, L. and Hao, S. 2014. Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities. PLoS One 9, e91463.
DOI
|
28 |
Amaya, C., Kurisetty, V., Stiles, J., Nyakeriga, A. M., Arumugam, A., Lakshmanaswamy, R., Botez, C. E., Mitchell, D. C. and Bryan, B. A. 2014. A genomics approach to identify susceptibilities of breast cancer cells to "fever-range" hyperthermia. BMC Cancer 14, 81.
DOI
|
29 |
Ahmed, K. and Zaidi, S. F. 2013. Treating cancer with heat: hyperthermia as promising strategy to enhance apoptosis. J. Pak. Med. Assoc. 63, 504-508.
|
30 |
Banerji, U. 2009. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 15, 9-14.
DOI
|
31 |
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., Tursz, T., Amigorena, S., Raposo, G., Angevin, E. and Zitvogel, L. 2002. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360, 295-305.
DOI
|
32 |
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., Stringaro, A., Molinari, A., Arancia, G., Gentile, M., Parmiani, G. and Fais, S. 2002. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195, 1303-1316.
DOI
|
33 |
Chu, K. F. and Dupuy, D. E. 2014. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer 14, 199-208.
DOI
|
34 |
Binder, R. J. and Srivastava, P. K. 2005. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6, 593-599.
|
35 |
Calderwood, S. K., Khaleque, M. A., Sawyer, D. B. and Ciocca, D. R. 2006. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31, 164-172.
DOI
|
36 |
Calderwood, S. K., Theriault, J. R. and Gong, J. 2005. How is the immune response affected by hyperthermia and heat shock proteins? Int. J. Hyperthermia 21, 713-716.
DOI
|
37 |
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J. P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., De Thonel, A., Multhoff, G., Hamman, A., Martin, F., Chauffert, B., Solary, E., Zitvogel, L., Garrido, C., Ryffel, B., Borg, C., Apetoh, L., Rebe, C. and Ghiringhelli, F. 2010. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457-471.
|
38 |
Chen, T., Guo, J., Yang, M., Zhu, X. and Cao, X. 2011. Chemokine-containing exosomes are released from heatstressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J Immunol. 186, 2219-2228.
DOI
|
39 |
Chicheł, A., Skowronek, J., Kubaszewska, M. and Kanikowski, M. 2007. Hyperthermia – description of a method and a review of clinical applications. Rep. Pract. Oncol. Radiother. 12, 267-275.
DOI
|
40 |
Cihoric, N., Tsikkinis, A., van Rhoon, G., Crezee, H., Aebersold, D. M., Bodis, S., Beck, M., Nadobny, J., Budach, V., Wust, P. and Ghadjar, P. 2015. Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials. gov registry. Int. J. Hyperthermia 31, 609-614.
DOI
|
41 |
Clayton, A., Mitchell, J. P., Court, J., Mason, M. D. and Tabi, Z. 2007. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 67, 7458-7466.
DOI
|
42 |
Dai, S., Wan, T., Wang, B., Zhou, X., Xiu, F., Chen, T., Wu, Y. and Cao, X. 2005. More efficient induction of HLA-A* 0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin. Cancer Res. 11, 7554-7563.
DOI
|
43 |
Endo, H., Yano, M., Okumura, Y. and Kido, H. 2014. Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis. 5, e1027.
DOI
|
44 |
Datta, N. R., Ordonez, S. G., Gaipl, U. S., Paulides, M. M., Crezee, H., Gellermann, J., Marder, D., Puric, E. and Bodis, S. 2015. Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat. Rev. 41, 742-753.
DOI
|
45 |
Dewhirst, M. W., Viglianti, B. L., Lora-Michiels, M., Hanson, M. and Hoopes, P. J. 2003. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int. J. Hyperthermia 19, 267-294.
DOI
|
46 |
Dickson, J. A. and Calderwood, S. K. 1980. Temperature range and selective sensitivity of tumors to hyperthermia: a critical review. Ann. N. Y. Acad. Sci. 335, 180-205.
DOI
|
47 |
Habash, R. W., Bansal, R., Krewski, D. and Alhafid, H. T. 2006. Thermal therapy, part 2: hyperthermia techniques. Crit. Rev. Biomed. Eng. 34, 491-542.
DOI
|
48 |
Frey, B., Weiss, E. M., Rubner, Y., Wunderlich, R., Ott, O. J., Sauer, R., Fietkau, R. and Gaipl, U. S. 2012. Old and new facts about hyperthermia-induced modulations of the immune system. Int. J. Hyperthermia 28, 528-542.
DOI
|
49 |
Fuggetta, M. P., Alvino, E., Tricarico, M., D′Atri, S., Pepponi, R., Prete, S. P. and Bonmassar, E. 2000. In vitro effect of hyperthermia on natural cell-mediated cytotoxicity. Anticancer Res. 20, 1667-1672.
|
50 |
Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M. and Spies, T. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93, 12445-12450.
DOI
|
51 |
Hildebrandt, B., Wust, P., Ahlers, O., Dieing, A., Sreenivasa, G., Kerner, T., Felix, R. and Riess, H. 2002. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 43, 33-56.
DOI
|
52 |
Harada, H., Murakami, T., Tea, S. S., Takeuchi, A., Koga, T., Okada, S., Suico, M. A., Shuto, T. and Kai, H. 2007. Heat shock suppresses human NK cell cytotoxicity via regulation of perforin. Int. J. Hyperthermia 23, 657-665.
DOI
|
53 |
Hedlund, M., Nagaeva, O., Kargl, D., Baranov, V. and Mincheva-Nilsson, L. 2011. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 6, e16899.
DOI
|
54 |
Heike, M., Noll, B. and Meyer zum Buschenfelde, K. H. 1996. Heat shock protein-peptide complexes for use in vaccines. J. Leukoc. Biol. 60, 153-158.
|
55 |
Hobohm, U. 2001. Fever and cancer in perspective. Cancer Immunol. Immunother. 50, 391-396.
|
56 |
Kennedy, D., Jager, R., Mosser, D. D. and Samali, A. 2014. Regulation of apoptosis by heat shock proteins. IUBMB Life 66, 327-338.
DOI
|
57 |
Horsman, M. R. and Overgaard, J. 2007. Hyperthermia: a potent enhancer of radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 19, 418-426.
DOI
|
58 |
Huber, V., Fais, S., Iero, M., Lugini, L., Canese, P., Squarcina, P., Zaccheddu, A., Colone, M., Arancia, G., Gentile, M., Seregni, E., Valenti, R., Ballabio, G., Belli, F., Leo, E., Parmiani, G. and Rivoltini, L. 2005. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128, 1796-1804.
DOI
|
59 |
Ischia, J. and So, A. I. 2013. The role of heat shock proteins in bladder cancer. Nat. Rev. Urol. 10, 386-395.
DOI
|
60 |
Ishii, T., Udono, H., Yamano, T., Ohta, H., Uenaka, A., Ono, T., Hizuta, A., Tanaka, N., Srivastava, P. K. and Nakayama, E. 1999. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol. 162, 1303-1309.
|
61 |
Iwata, K., Shakil, A., Hur, W. J., Makepeace, C. M., Griffin, R. J. and Song, C. W. 1996. Tumour pO2 can be increased markedly by mild hyperthermia. Br. J. Cancer Suppl. 27, S217- 221.
|
62 |
Jego, G., Hazoume, A., Seigneuric, R. and Garrido, C. 2013. Targeting heat shock proteins in cancer. Cancer Lett. 332, 275-285.
DOI
|
63 |
Kim, H., Park, B. K. and Kim, C. K. 2008. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma. Kor. J. Radiol. 9, 470-472.
DOI
|
64 |
Mallory, M., Gogineni, E., Jones, G. C., Greer, L. and Simone, C. B. 2nd. 2016. Therapeutic hyperthermia: The old, the new, and the upcoming. Crit. Rev. Oncol. Hematol. 97, 56-64.
DOI
|
65 |
Kim, J. Y., Son, Y. O., Park, S. W., Bae, J. H., Chung, J. S., Kim, H. H., Chung, B. S., Kim, S. H. and Kang, C. D. 2006. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp. Mol. Med. 38, 474-484.
DOI
|
66 |
Kim, S. J., Ha, G. H., Kim, S. H. and Kang, C. D. 2014. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. Immunol. Invest. 43, 517-534.
DOI
|
67 |
Labani-Motlagh, A., Israelsson, P., Ottander, U., Lundin, E., Nagaev, I., Nagaeva, O., Dehlin, E., Baranov, V. and Mincheva-Nilsson, L. 2016. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity. Tumour Biol. 37, 5455-5466.
DOI
|
68 |
Lanneau, D., Brunet, M., Frisan, E., Solary, E., Fontenay, M. and Garrido, C. 2008. Heat shock proteins: essential proteins for apoptosis regulation. J. Cell Mol. Med. 12, 743-761.
DOI
|
69 |
Lepock, J. R. 2003. Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage. Int. J. Hyperthermia 19, 252-266.
DOI
|
70 |
Lopez-Soto, A., Huergo-Zapico, L., Acebes-Huerta, A., Villa-Alvarez, M. and Gonzalez, S. 2015. NKG2D signaling in cancer immunosurveillance. Int. J. Cancer 136, 1741-1750.
DOI
|
71 |
Marleau, A. M., Chen, C. S., Joyce, J. A. and Tullis, R. H. 2012. Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med. 10, 134.
DOI
|
72 |
Multhoff, G. 1997. Heat shock protein 72 (HSP72), a hyperthermia-inducible immunogenic determinant on leukemic K562 and Ewing's sarcoma cells. Int. J. Hyperthermia 13, 39-48.
DOI
|
73 |
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez Gracia, J. L. and Haanen, J. 2015. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472.
DOI
|
74 |
Mincheva-Nilsson, L. and Baranov, V. 2014. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin. Cancer Biol. 28, 24-30.
DOI
|
75 |
Morimoto, R. I. 1998. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 12, 3788-3796.
DOI
|
76 |
Rampersaud, E. N., Vujaskovic, Z. and Inman, B. A. 2010. Hyperthermia as a treatment for bladder cancer. Oncology (Williston Park) 24, 1149-1155.
|
77 |
Multhoff, G., Botzler, C., Wiesnet, M., Eissner, G. and Issels, R. 1995. CD3- large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 86, 1374-1382.
|
78 |
Multhoff, G., Botzler, C., Wiesnet, M., Muller, E., Meier, T., Wilmanns, W. and Issels, R. D. 1995. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int. J. Cancer 61, 272-279.
DOI
|
79 |
Piper, P. W. and Millson, S. H. 2011. Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals 1400-1422.
|
80 |
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. and Jung, H. 2013. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413-441.
DOI
|